Sphera Funds Management’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-28,600
Closed -$1.53M – 122
2026
Q2
$1.53M Sell
28,600
-22,200
-44% -$982K 0.2% 92
2026
Q1
$2.45M Buy
50,800
+9,800
+24% +$671K 0.39% 73
2025
Q4
$2.85M Sell
41,000
-132,931
-76% -$5.43M 0.55% 65
2025
Q3
$4.87M Buy
173,931
+78,000
+81% +$1.55M 1.03% 33
2025
Q2
$1.99M Buy
95,931
+11,931
+14% +$262K 0.47% 69
2025
Q1
$1.45M Buy
+84,000
New +$2.06M 0.33% 77

Other funds holding GPCR

Sphera Funds Management's GPCR Position: Q3 2026 in Review

Sphera Funds Management sold out of Structure Therapeutics (GPCR) in Q3 2026, closing a stake of 28,600 shares — an estimated $1.53M sold.

Sphera Funds Management first reported a position in GPCR in Q1 2025 and held it in 6 quarters. The position peaked at $4.87M in Q3 2025. 169 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Sphera Funds Management reported no remaining Structure Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Sphera Funds Management sold 28,600 Structure Therapeutics shares in Q3 2026, an estimated $1.53M.
  • Sphera Funds Management first reported a position in Structure Therapeutics in Q1 2025 and held it in 6 quarters.
  • Sphera Funds Management's Structure Therapeutics position peaked at $4.87M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Sphera Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.